Silver Crown Royalties Inc

Bristol Myers Squibb and Sarah Cannon Research Institute Expand Strategic Collaboration to Accelerate Cancer Clinical Trials

- Bristol Myers Squibb and Sarah Cannon Research Institute announced an expanded strategic collaboration to accelerate innovative cancer therapy development and increase clinical trial access across the U.S. - The collaboration achieved a 45% reduction in study startup timelines across eight Bristol Myers Squibb clinical trials, significantly outperforming non-SCRI sites. - SCRI's Accelero model streamlines operations across more than 200 locations with over 1,300 physicians, bringing cutting-edge research directly to patients in community settings. - The partnership emphasizes health equity by improving access to clinical trials for medically underserved populations through data-driven strategies and community-based care.